Efficacy, cycle control, tolerance, and adverse events were studied in a clinical Phase IV
study using a new progestogen, gestodene, in an amount of 75 μg combined with 30 μg …

The aim of this study was to compare contraceptive reliability, cycle control, and tolerance of
an oral contraceptive containing 20 μg ethinylestradiol (EE2) and 75 μg gestodene (GSD) …

The aim of this study was to compare contraceptive reliability, cycle control and tolerance of
an oral contraceptive containing 20 μg ethinylestradiol and 75 μg gestodene, with a …

Oral contraceptives (OCs) are, or perhaps more correctly, were, until recently, being taken by
approximately 65 million women worldwide, which corresponds to approximately 6% of all …

Two monophasic oral contraceptives containing gestodene (GTD, 15 μg) and
ethinylestradiol (EE, 30 μg) or norgestimate (NGS, 250 μg) and EE (35 μg) were compared …

In a large and open prospective multicenter trial of 12,250 cycles from 2,378 women,
contraceptive efficacy, clinical tolerance and acceptability of a new monophasic …

Results are presented of a Phase III international multicentre trial to study the effect of a new
low-dose oral contraceptive (OC) containing 20 μg ethinylestradiol and 150 μg desogestrel …

The monophasic combination preparation containing 30 micrograms ethinyl estradiol and
75 micrograms gestodene was tested for contraceptive reliability, cycle control and …

Although the use of oral contraceptives has been frequently associated with an increased
risk of thromboembolic events, definitive prothrombotic mechanisms have not so far been …

This long-term, open-label, multicenter study investigated the clinical efficacy and tolerability
of a monophasic oral contraceptive containing 20 μg ethinylestradiol and 75 μ ggestodene …